Alpha Teknova, Inc.
NNASDAQ:TKNOCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Stephen Gunstream
- Full Time Employees
- 158
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 2290 Bert Drive Hollister CA United States 95023
- IPO Date
- Jun 25, 2021
- CIK
- 0001850902
- Website
- teknova.com
- Similar Companies
- Business
- Alpha Teknova, Inc. (Nasdaq: TKNO) manufactures and supplies critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company offers lab essentials, including chemical formulations such as pre-poured agar plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, buffers, molecular biology reagents for sample manipulation, resuspension and purification, additives including amino acids, vitamins, minerals, IPTG and trace metals, as well as water for injection (WFI) quality water; and clinical solutions encompassing custom GMP-grade products for protein therapies, gene therapies, mRNA vaccines and diagnostic kits, available in formats including bottles, single-use bags from 1L to 200L, and cryopreservation media. Alpha Teknova serves pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic firms, academic institutions and government research entities in the life sciences market, with operations centered in the United States and international distribution. Founded in 1996 by Genentech scientist Ted Davis in Half Moon Bay, California, the company maintains headquarters at 2451 Bert Drive, Hollister, California. Alpha Teknova reports 2024 revenue of $37.7 million, reflecting 3% year-over-year growth, and provides 2025 guidance of $39-42 million; in July 2024, major shareholder Telegraph Hill Partners purchased approximately $15 million in shares at $1.24 each through private placement, increasing its stake to over 25 million shares; recent product launches include Tryptic Soy Agar settle plates for environmental monitoring, PluriFreeze cryopreservation system via collaboration with Pluristyx for allogeneic cell therapies, RUO+ manufacturing grade and Express- Tek production services for rapid custom formulations, alongside expanded single-use bag offerings and custom quality control testing.
Company News
Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Has Consensus Price Target of $8.75 According to Analysts
Alpha Teknova Q3 Earnings Call Highlights
Alpha Teknova, Inc. (TKNO) Q3 2026 Earnings Call Transcript
Alpha Teknova (TKNO) Reports Q3 Loss, Tops Revenue Estimates
Teknova Reports Third Quarter 2026 Financial Results
Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells
Alpha Teknova (TKNO) Stock Jumps 5.1%: Will It Continue to Soar?
Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026
Teknova Announces Pricing of $40 Million Public Offering of Common Stock
Teknova Announces Proposed Public Offering of Common Stock
Teknova Announces Preliminary Third Quarter Financial Results
Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze
Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System
All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy
Head-To-Head Survey: Alpha Teknova (NASDAQ:TKNO) and Icon (NASDAQ:ICLR)
88,412 Alpha Teknova, Inc. $TKNO Shares Sold by Squarepoint Ops LLC
Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?
Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling
Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference
Alpha Teknova (TKNO) is a Great Momentum Stock: Should You Buy?